Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Merck & Co., Inc. (NYSE: MRK ) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-001 study, intismeran plus Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. No new safety concerns emerged. Investors are now asking whether intismeran can turn Keytruda from a drug approaching a patent cliff into the foundation of a personalized-cancer platform.

That distinction matters because Merck & Co., Inc. (NYSE:MRK) generated $31.68 billion from Keytruda and Keytruda Qlex in 2025, nearly half of the company's sales. In the U.S., biosimilar competition could begin after Keytruda's primary compound patent expires in December 2028, although biosimilars have already entered some smaller international markets. A successful combination could support continued use of the franchise without removing the need for other growth engines.

The bullish case for Merck & Co., Inc. (NYSE:MRK) is that intismeran adds a personalized immune response to a checkpoint inhibitor already embedded across oncology. The treatment is designed from the unique mutations in each patient's tumor and encodes as many as 34 neoantigens, training the immune system to recognize tumor cells while Keytruda removes a brake on the immune response.

Earlier Phase 2b data showed a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death at five years. Phase 3 confirmation makes the approach more credible for Merck & Co., Inc. (NYSE:MRK) beyond melanoma. The company is also studying intismeran combinations in non-small cell lung, bladder and renal-cell cancers. Success across several tumor types could create a portfolio of Keytruda combinations rather than a single indication.

That would give Merck & Co., Inc. (NYSE:MRK) another lifecycle-management tool alongside Keytruda Qlex and newer oncology assets. It also strengthens the argument that Keytruda can remain commercially relevant after standalone pembrolizumab faces lower-priced competition.

The rally asks investors to value a platform before seeing the pivotal numbers. Merck & Co., Inc. (NYSE:MRK) and Moderna did not disclose the Phase 3 effect sizes, while overall-survival results are not yet available and will be evaluated as the study continues. Approval, pricing and reimbursement remain unresolved.

The economics are less powerful than those of wholly owned Keytruda. Merck & Co., Inc. (NYSE:MRK) and Moderna share development costs and any profits equally worldwide. Each patient's therapy must be custom-designed and produced using the unique mutational signature identified from that patient's tumor sample, adding production, turnaround-time, and delivery challenges. Payers must also accept the cost of personalized therapy on top of checkpoint inhibition.

Intismeran extends the Keytruda ecosystem; it does not independently replace $31.68 billion of annual franchise sales for Merck & Co., Inc. (NYSE:MRK). Multiple successful indications would be needed for the economics to approach that scale.